Aptevo Therapeutics (APVO) Capital Expenditures (2015 - 2022)
Aptevo Therapeutics (APVO) posted Capital Expenditures of $4000.0 for Q3 2022, down 96.61% sequentially from $118000.0 in Q4 2021, and down 69.23% YoY from $13000.0 in Q3 2021.
Aptevo Therapeutics (APVO) Capital Expenditures (2015 - 2022) Analysis & Trends
Aptevo Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at $4000.0 in Q3 2022.
- Quarterly Capital Expenditures fell 69.23% year-over-year to $4000.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was $135000.0 (down 81.07% YoY) and the FY2022 annual result came in at $29000.0, down 95.93% from the prior year.
- Capital Expenditures fell to $4000.0 in Q3 2022 per APVO's latest filing, from $118000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $927000.0 in Q3 2018 and troughed at $4000.0 in Q3 2022.
- A 4-year average of $315222.2 and a median of $191000.0 in 2021 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2018 and 2022: Capital Expenditures jumped 586.67% in 2018, then sank 69.23% in 2022.
- Over 4 years, Capital Expenditures stood at $927000.0 in 2018, then slumped by 83.5% to $153000.0 in 2019, then dropped by 22.88% to $118000.0 in 2021, then tumbled by 96.61% to $4000.0 in 2022.
- According to Business Quant data, Capital Expenditures over the past three periods registered $4000.0, $118000.0, and $13000.0 for Q3 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 4,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Dec 31, 2021 | 118,000.00 |
| Dec 31, 2021 | 118,000.00 |
| Sep 30, 2021 | 13,000.00 |
| Sep 30, 2021 | 13,000.00 |
| Jun 30, 2021 | 391,000.00 |
| Jun 30, 2021 | 391,000.00 |
| Mar 31, 2021 | 191,000.00 |
| Mar 31, 2021 | 191,000.00 |
| Mar 31, 2019 | 153,000.00 |
| Mar 31, 2019 | 153,000.00 |
| Sep 30, 2018 | 927,000.00 |
| Sep 30, 2018 | 927,000.00 |
| Jun 30, 2018 | 567,000.00 |
| Jun 30, 2018 | 567,000.00 |
| Mar 31, 2018 | 473,000.00 |
| Mar 31, 2018 | 473,000.00 |
| Dec 31, 2017 | 297,000.00 |
| Dec 31, 2017 | 297,000.00 |